한빛사
>
한빛사논문
한빛사논문
- 조회113
임가영Gayoung Lim
한양대학교
ACS Nano, Aug 19 2025, | https://doi.org/10.1021/acsnano.5c09985
Mucoadhesive and Self-Assembled Chitosan Oligosaccharide-Glycyrrhizin Nanoparticle for Oral Nanotherapeutic in Inflammatory Bowel Disease
Gayoung Lim 1 †, Ha Rin Kim 2 3 †, Chaerim Yoo 1 †, Yu Kyung Oh 1, Yeon Soo Park 1, Sijin Park 1 4, Seonmi Jang 1, Lia Priscilla 1 4, Dong Yun Lee 1 4 5 *
1Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04763, Republic of Korea.
2Division of Oncology, School of Medicine, Stanford University, Stanford, California 94305, United States.
3Biopharmaceutical Chemistry, Applied Chemistry, Kookmin University, Seoul 02707, Republic of Korea.
4Elixir Pharmatech Inc., Seoul 04763, Republic of Korea.
5Institute for Bioengineering and Biopharmaceutical Research (IBBR), and Institute of Nano Science and Technology (INST), Hanyang University, Seoul 04763, Republic of Korea.
2Division of Oncology, School of Medicine, Stanford University, Stanford, California 94305, United States.
3Biopharmaceutical Chemistry, Applied Chemistry, Kookmin University, Seoul 02707, Republic of Korea.
4Elixir Pharmatech Inc., Seoul 04763, Republic of Korea.
5Institute for Bioengineering and Biopharmaceutical Research (IBBR), and Institute of Nano Science and Technology (INST), Hanyang University, Seoul 04763, Republic of Korea.
†These authors contributed equally
*Corresponding author: correspondence to Dong Yun Lee
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by severe oxidative stress and intestinal barrier dysfunction. Conventional oral therapies are often limited by low bioavailability and off-target effects. Herein, we report the development of mucoadhesive nanotherapeutics engineered from low molecular weight chitosan oligosaccharide (COS) and glycyrrhizin (GL), a natural anti-inflammatory compound. Hydrophilic COS, selected for its potent antioxidant and mucoadhesive properties, was chemically conjugated with hydrophobic GL to facilitate self-assembly into stable COS-GL nanoparticles (∼129 nm). These nanoparticles exhibit enhanced retention at inflamed intestinal sites and preferential uptake by activated immune and epithelial cells. In vitro evaluations using transwell coculture systems and intestinal organoids revealed that COS-GL nanoparticles effectively suppress pro-inflammatory cytokine secretion, promote M1-to-M2 macrophage remodeling, neutralize reactive oxygen species (ROS), and restore intestinal barrier integrity by upregulating tight junction proteins. In a DSS-induced colitis mouse model, orally administered COS-GL nanoparticles outperform both their individual components and the standard therapeutic 5-aminosalicylic acid (5-ASA), mitigating inflammation and promoting mucosal healing. These findings establish COS-GL nanoparticles as a promising and effective nanotherapeutic platform for the targeted oral treatment of IBD.
논문정보
- Research article
- 2025년 08월 (BRIC 등록일 2025-08-21)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
관련분야 논문보기
